Press Release For Immediate Release

Glenmark confirms settlement for Hydrocortisone Butyrate

May 25, 2011: Glenmark Pharmaceuticals Limited and Glenmark Generics Inc., USA ("Glenmark") have entered into a settlement and license agreement with Triax Pharmaceuticals, LLC, Astellas Pharma Europe B.V. and Astellas Pharma International B.V. ("Astellas and Triax") to resolve a United States patent infringement suit related to Glenmark's filing of an abbreviated new drug application ("ANDA") for 0.1% hydrocortisone butyrate cream, Glenmark's generic version of Locoid Lipocream®.

Subject to the terms of the settlement and license Agreement, Glenmark will be permitted to market and distribute Glenmark's 0.1% hydrocortisone butyrate cream under a royalty-bearing license from Astellas and Triax in the United States near the end of 2013. Glenmark believes that it is entitled to 180 days of exclusivity with respect to its hydrocortisone butyrate cream, as the first generic company to file an ANDA for the product.

Locoid Lipocream® is available as a 0.1% hydrocortisone butyrate topical corticosteroid cream. According to IMS Health data, for 2010, Locoid Lipocream® achieved sales of approximately USD 38 million.

About Glenmark Generics limited.
Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries. It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 63 countries, including the US, various countries in the EU, South America and India.

#####

For further information, please contact:
Jason D'Souza
Glenmark, Mumbai, India Tel: [+91 22] 40189919
Email : connect@glenmark-generics.com